国际医学(000516) - 2024 Q2 - 季度业绩预告

Current Period Performance Forecast The company forecasts a net loss for the first half of 2024, with a significant reduction in the loss amount compared to the prior year, alongside an expected increase in operating revenue - The performance forecast period is from January 1 to June 30, 2024, with an anticipated net loss[2] Key Performance Forecast Data for H1 2024 | Indicator | Estimated for Current Period | Same Period Last Year | Trend | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company (Million CNY) | Loss: 168.00 – 176.00 | Loss: 222.26 | Loss Narrowed | | Net Profit After Deducting Non-Recurring Gains and Losses (Million CNY) | Loss: 132.00 – 142.00 | Loss: 254.89 | Loss Significantly Narrowed | | Basic Earnings Per Share (CNY/share) | Loss: 0.0743 – 0.0778 | Loss: 0.0977 | Loss Per Share Decreased | | Operating Revenue (Billion CNY) | 2.40 – 2.45 | 2.21 | Continued Growth | Communication with Accounting Firm The company explicitly states that the financial data presented in this performance forecast remains unaudited by a certified public accountant - The financial data in this performance forecast has not been audited by a certified public accountant[5] Explanation of Performance Changes The company's H1 2024 net loss primarily stems from insufficient operating revenue to cover period expenses, yet its core medical business shows steady growth, increased service volume, and improved gross margins, leading to a narrowed loss - The core reason for the net loss is that the operating revenue scale has not yet covered period expenses[6][13] - The company's operations show positive development, with a stable core medical business, increased service volume, sustained revenue growth, and a year-over-year narrowing of the loss margin[13] Other Relevant Information The company emphasizes that this performance forecast represents preliminary, unaudited financial department estimates, with final accurate data to be disclosed in the 2024 semi-annual report, advising investors of associated risks - This performance forecast is a preliminary, unaudited estimate by the company's finance department, with final data subject to the official semi-annual report[7]